Thromb Haemost 1995; 74(03): 987-989
DOI: 10.1055/s-0038-1649860
Scientific and Standarolzation Committee Communications
Schattauer GmbH Stuttgart

Comparison of Six Commercial Plasma References for Factor VIII, Factor IX and von Willebrand Factor

On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH
Carol K Kasper
1   The Orthopaedic Hospital University of Southern California, Los Angeles, California, USA
,
David L Aronson
2   The George Washington University Medical Center, Washington D.C., USA
,
George Davignon
3   The University of California, San Diego, California, USA
,
Paul Foster
4   The Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin, USA
,
Carol Hillman-Wiseman
5   The Children’s Hospital of Michigan, Wayne State University, Detroit, Michigan
,
Jeanne M Lusher
5   The Children’s Hospital of Michigan, Wayne State University, Detroit, Michigan
,
Marilyn Manco-Johnson
6   The University of Colorado Health Sciences Center, Denver, Colorado,USA
,
James B Meade
7   The University of North Carolina Hospitals, Chapel Hill, North Carolina, USA
,
Robert R Montgomery
4   The Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin, USA
,
Frederick R Rickies
8   The University of Connecticut Health Center, Farmington, Connecticut, USA
,
Gilbert C White II
7   The University of North Carolina Hospitals, Chapel Hill, North Carolina, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

Summary

Six brands of normal reference plasma produced in the United States, with assigned assay values for factor VIII and IX and, in four instances, ristocetin cofactor and von Willebrand antigen, were assayed in nine coagulation laboratories in academic institutions in the same country. Differences in mean assays of reference plasmas, as a percent of labelled potency, were significant and were greater than differences among laboratories. Standard methods of assigning potency to commercial reference plasmas are recommended.

 
  • References

  • 1 Barrowcliffe TW, Kirkwood TB L. Standardization of factor VIII. 1. Calibration of British Standards for factor VIII clotting activity Br J Haematol 1980; 46: 471-481
  • 2 Kirkwood TB L, Barrowcliffe TW. Standardization of factor VIII. 2. A British standard for factor VIII related antigen Br J Haematol 1980; 46: 483-490
  • 3 Barrowcliffe TW, Tydeman MA, Kirkwood TB L, Thomas DP. Standardization of factor VIII. III. Establishment of a stable reference plasma for factor VHI-related activities Thromb Haemost 1983; 50: 690-696
  • 4 WHO Technical Report Series. 1983; 687: 23-24
  • 5 WHO Technical Report Series. 1989; 786: 20-21
  • 6 Heath AB, Barrowcliffe TW. Standardization of factor VIII. V. Calibration of the 2nd Inlcrnalional Standard for factor VIII and von Willebrand factor activities in plasma Thromb Haemost 1992; 68: 155-159
  • 7 WHO Technical Report Series. 1994; 840: 7-8
  • 8 Gabra GS, Prowsc CV, Boulton FE. Importance of a quality assurance scheme for factor VIII assays in quality monitoring of human plasma destined for fractionation into factor VIII concentrate. Vox Sang 1989; 56: 65-70